Vaccine efficacy induced by virus-like particles containing Leishmania donovani surface glycoprotein GP63

Keon-Woong Yoon,Ki Back Chu,Gi-Deok Eom,Jie Mao,Fu-Shi Quan

DOI: https://doi.org/10.1371/journal.pntd.0012229

2024-06-11

PLoS Neglected Tropical Diseases

Abstract:Leishmania donovani surface glycoprotein 63 (GP63) is a major virulence factor involved in parasite escape and immune evasion. In this study, we generated virus-like particles (VLPs) expressing L . donovani GP63 using the baculovirus expression system. Mice were intramuscularly immunized with GP63-VLPs and challenged with L . donovani promastigotes. GP63-VLP immunization elicited higher levels of L . donovani antigen-specific serum antibodies and enhanced splenic B cell, germinal center B cell, CD4 + , and CD8 + T cell responses compared to unimmunized controls. GP63-VLPs inhibited the influx of pro-inflammatory cytokines IFN-γ and IL-6 in the livers, as well as thwarting the development of splenomegaly in immunized mice. Upon L . donovani challenge infection, a drastic reduction in splenic parasite burden was observed in VLP-immunized mice. These results indicate that GP63-VLPs immunization conferred protection against L . donovani challenge infection by inducing humoral and cellular immunity in mice. Visceral leishmaniasis is a neglected tropical disease that can be fatal in humans if left untreated. Unfortunately, despite the urgent need, an efficacious vaccine for this parasitic disease continues to remain under development. Though challenging, we attempted to develop an experimental leishmaniasis vaccine using the highly immunogenic virus-like particle (VLP) platform that expressed the glycoprotein 63 antigen of Leishmania donovani , a causative agent of visceral leishmaniasis. We used this vaccine to immunize mice and after two immunizations, mice were challenge infected with L . donovani to assess vaccine-induced protection. Our results revealed that compared to the unimmunized control mice, mice immunized with the experimental vaccines were well-protected against developing visceral leishmaniasis. Specifically, VLP vaccine immunization ensured that immune responses necessary for protection were induced to high levels and this contributed to suppressing leishmaniasis-associated pathologies as well as the parasite propagation in mice. Overall, we demonstrated that this VLP-based vaccine can elicit adequate protection against visceral leishmaniasis and propose further research to enhance and optimize its efficacy.

tropical medicine,parasitology